Unlocking the Power of Aptamers to Deliver Targeted Treatments
Triera Biosciences is pioneering a transformative aptamer platform with breakthrough potential for development of new treatments. Preclinical trials have demonstrated efficacy that have matched or exceeded monoclonal antibodies.
What if we could develop treatments faster, more economically, and more effectively?
The global health picture in the 21st century clearly illustrates the need for new dynamic health solutions. Global pandemics, evolving viruses, and an increasing senior population worldwide demand a faster and more effective approach.
Triera Biosciences is demonstrating the incredible potential of aptamers to create treatment platforms that are equal parts groundbreaking, effective, and accessible.
Speed to Drug Discovery
The process to select aptamer candidates for use is rapid and can be done within weeks.
Greater Consistency
Aptamers are synthesized via digital sequence, improving on consistency, safety, and quality.
Cost to Develop
With well-defined targets, lab-synthesized aptamers eliminate the need for costly animal models.
Triera Biosciences is tackling complex challenges with cutting-edge aptamer technology. Join us.
How Triera is Overcoming Past Aptamer Challenges
Until now, five common challenges have prevented aptamers from wider utilization –five challenges the research and development already undertaken by Triera Biosciences have addressed.
Challenge
The Triera Solution
Size and Bioavailability – Aptamers are often too small to stay in the body, leading to rapid renal clearance and insufficient bioavailability.
Our aptamer technology increases bioavailability – meaning aptamers stay in place long enough to do their job.
Allergic Reactions to PEG – Polyethylene glycol (PEG) is often added to increase the molecular weight of aptamers. However, PEG can trigger allergic reactions in a small percentage of people.
Our aptamer technology does not require PEG, eliminating the risk of these allergic reactions.
Enzyme Degradation – Aptamers are susceptible to degradation by enzymes in the body, reducing their efficacy.
Our aptamer technology leverages recent advancements to create an aptamer with greater endurance.
Our technology selected a universal aptamer that bound to the conserved receptor binding domain of the SARS-CoV-2 spike protein, extending the effectiveness of C19HBA against all known variants.
Patents – Aptamers in their original form have been protected by rigorous patents, including the SELEX process. Expiration of the patents has opened the door to innovation
Our patent builds on the original research, but with a different form. This allows new patents and ability to overcome previous challenges. We have a growing portfolio of provisional patents that protect the discoveries we have made that overcome the previous challenges of aptamers and unlock their potential.
Zentek and McMaster University Announce New Aptamer Technology Platform
